432A — Cliniphar Share Price
Last trade - 00:00- ¥1bn
- ¥3bn
- ¥4bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.43 | ||
| Price to Tang. Book | 1.43 | ||
| Price to Free Cashflow | 27.45 | ||
| Price to Sales | 0.4 | ||
| EV to EBITDA | 16.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.54% | ||
| Return on Equity | 20.19% | ||
| Operating Margin | 3.77% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | n/a | n/a | 3,526.31 | 3,585.61 | n/a | n/a | 1.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cliniphar Ltd is a Japan-based company primarily engaged in the pharmaceutical wholesale business. The Company operates its businesses through the pharmaceutical wholesale segment. The Segment supplies prescription and over-the-counter drugs in Japan to domestic and international customers who possess the appropriate licenses, including medical institutions, pharmacies and peer wholesalers. The Company also manages group operations, including the operation, system development and maintenance of its pharmaceutical e-commerce (EC) platform. The Company is also engaged in sales operations, procurement and product management. The Company also accepts traditional order methods including telephone, email and fax, maintaining a stable and flexible supply system alongside online orders. The Company is focusing on its domestic and international e-commerce platforms named Kosei Market and synapse, which embody the digital transformation (DX) of pharmaceutical distribution.
Directors
- Last Annual
- March 31st, 2025
- Last Interim
- January 1st, 1970
- Incorporated
- January 13th, 2017
- Public Since
- October 7th, 2025
- No. of Employees
- 15
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 1,000,000
- Address
- 5F, OMM Bldg., 1-7-31, Otemae, Chuo-ku, OSAKA-SHI, 540-0008
- Web
- https://cliniphar.com/
- Phone
- +81 669419288
- Auditors
- FRIQ Audit Corporation
Similar to 432A
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 11:00 UTC, shares in Cliniphar are trading at ¥1,450. This share price information is delayed by 15 minutes.
Shares in Cliniphar last closed at ¥1,450 and the price had moved by over the past 365 days. In terms of relative price strength the Cliniphar share price has matched the Nikkei 225 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreCliniphar does not currently pay a dividend.
Cliniphar does not currently pay a dividend.
Cliniphar does not currently pay a dividend.
To buy shares in Cliniphar you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,450, shares in Cliniphar had a market capitalisation of ¥1bn.
Here are the trading details for Cliniphar:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 432A
Based on an overall assessment of its quality, value and momentum Cliniphar is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cliniphar. Over the past six months, its share price has matched the Nikkei 225 Index by .
As of the last closing price of ¥1,450, shares in Cliniphar were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cliniphar PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥1,450.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Cliniphar's directors